Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting

ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Basel, June 3, 2023 – OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma (download poster here).

Latest News

19.05.2025

Basel Area Life-Science Ecosystem – Handelszeitung

Basel, May 15, 2025: See Anaveon’s contribution to the Handelszeitung special report on the status of Life Sciences in Basel: Handelszeitung
Read more

01.04.2025

Immuno-Oncology Progress: PragmaTIL Trial Receives Approval, with Anaveon as a Key Partner

As a key partner, we are proud to announce that PragmaTIL has received regulatory approval to launch its clinical trial, bringing safer and more effective cell therapy one step closer to cancer patients. 🔬 The trial will start at VHIO (Spain) and Herlev Hospital (Denmark),…
Read more

18.12.2024

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Basel, December 18, 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective February 1, 2025. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and…
Read more

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com